Astellas Pharma US | Changing Tomorrow

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib) Read More

Astellas Helps Veterans Compete in 2019 Warrior Games Read More

Check out The Astellas Way Blog to hear our executives' thoughts on moments and trends in the industry and what's on the horizon for our company

Astellas Announces Collaboration with the Jewish Association Serving the Aging (JASA) to Improve Chronic Disease and Bladder Health Management Read More

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

News

Latest

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Media

Jul 17, 2019

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

News / Corporate

Aug 21, 2019

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

News / Corporate

Aug 06, 2019

Astellas Announces Appointment of David Fryrear as New Global Head of Clinical and Research Quality Assurance Organization

News / Corporate

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

View All >>